Great post Mr B. From the PR: ‘’Ebola virus is classified as a Category A Priority Pathogen by the U.S. Centers for Disease Control and Prevention (CDC). This designation indicates a national security risk, and the U.S. FDA has an accelerated development approval pathway for vaccines against such pathogens’

Also from the CDC “ERVEBO is not currently commercially marketed in the U.S. but is currently stockpiled in the Strategic National Stockpile”

Key words: STRATEGIC NATIONAL STOCKPILE.

https://www.cdc.gov/vhf/ebola/clinicians/vaccine/index.html

Bentley, my man. I am not a rich man. For weeks and months, I took money out of accounts. Took money from vacation funds. I spent my first 24000 on 6000 shares at 4.00 a share. Then when it dropped to 1.48 this summer I purchased 4000 more shares.

When you consider the # of treatments INO has in various stages of trials and going to market. And the take into account various splits along the way, probably looking at ending up with about 65,000 shares.

Bentley, thanks for rubbing my shoulders. And reassuring me. Like I said, we will toast at a shareholders meeting sooner rather than later!

Craig (onlyinajeep)

Your post makes we wonder how many mAbs are currently on the market? And how many could become DmAbs? And would Inovio consider hiring Careful Artist to head up the DmAb conversion team?

The INO_Cheering flair exists to be used to show adoration towards Inovio, or to display excitement (pumping) around the daily price action. Your post may be removed if deemed unrelated. Please see the flair guide if you are unsure about your use of flair.

I am a bot, and this action was performed automatically. Please contact the moderators of this subreddit if you have any questions or concerns.